Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush

Scholar Rock (NASDAQ:SRRK - Get Free Report)'s stock had its "outperform" rating restated by analysts at Wedbush in a report issued on Wednesday,RTT News reports. They currently have a $50.00 price target on the stock. Wedbush's price target indicates a potential upside of 37.67% from the stock's previous close.

Separately, Lifesci Capital raised shares of Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $42.67.

Scholar Rock Stock Performance

Shares of SRRK traded up $5.17 during trading hours on Wednesday, reaching $36.32. 5,286,060 shares of the company traded hands, compared to its average volume of 1,295,393. The stock's fifty day moving average is $31.32 and its 200 day moving average is $36.09. The stock has a market cap of $3.45 billion, a P/E ratio of -14.36 and a beta of 0.28. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter last year, the business earned ($0.59) EPS. Equities research analysts anticipate that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey S. Flier sold 6,075 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.73, for a total transaction of $180,609.75. Following the completion of the sale, the director now owns 24,070 shares of the company's stock, valued at approximately $715,601.10. This trade represents a 20.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tracey Sacco sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $33.08, for a total transaction of $215,020.00. Following the sale, the insider now directly owns 71,750 shares of the company's stock, valued at approximately $2,373,490. The trade was a 8.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,500 shares of company stock worth $1,181,671 over the last quarter. Company insiders own 13.30% of the company's stock.

Institutional Trading of Scholar Rock

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC boosted its stake in Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after acquiring an additional 3,439,215 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Scholar Rock by 7.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock valued at $401,231,000 after acquiring an additional 629,315 shares during the last quarter. Vanguard Group Inc. boosted its stake in Scholar Rock by 2.1% in the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company's stock valued at $155,773,000 after acquiring an additional 101,723 shares during the last quarter. Marshall Wace LLP boosted its stake in Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after acquiring an additional 2,732,546 shares during the last quarter. Finally, Bellevue Group AG boosted its stake in Scholar Rock by 16.2% in the fourth quarter. Bellevue Group AG now owns 2,510,690 shares of the company's stock valued at $108,512,000 after acquiring an additional 349,487 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.